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Abstract
Background: Due to a lack of consensus on adjuvant treatments for pT1N1 gastric cancer, surgeons face a dilemma
when deciding treatments for patients with pT1N1 gastric cancer after gastrectomy. The objective of this study was to
determine survival benefits of adjuvant chemotherapy and risk factors for tumor recurrence in gastric cancer patients
with pT1N1.
Methods: Between 1996 and 2010, 510 patients who underwent curative resection for pT1N1 gastric cancer at three
institutes were divided into two groups: adjuvant chemotherapy group (N = 150) and surgery-only group (N = 360).
Disease-free survival rates and risk factors for tumor recurrence were analyzed.
Results: During the median follow-up of 78 months, 7.5% of patients experienced tumor recurrence (7.3% in adjuvant
chemotherapy group and 7.5% in surgery-only group). The 5-year disease-free survival rate was 91.8% in the adjuvant
chemotherapy group and 94.6% in the surgery-only group without significant difference between the two. In
univariate analysis, older age (>65 years), male gender, body mass index <25 kg/m2, elevated gross type, and
differentiated histology were associated with tumor recurrence. Multivariate analysis showed that advanced age
and male gender were independent risk factors for tumor recurrence. In addition, adjuvant chemotherapy
showed no benefitial effect on tumor recurrence in pT1N1 gastric cancer.
Conclusions: Adjuvant chemotherapy did not show any oncologically benefitial effect on tumor recurrence, it
might be unnecessary for pT1N1 gastric cancer after curative surgery.
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Background
According to the National Comprehensive Cancer Network
(NCCN) Guidelines (Version 2.2013, Gastric Cancer), treat-
ment for patients with pT1N1 gastric cancer confined to
the mucosa or submucosa with one or two regional lymph
node metastases should include adjuvant chemotherapy
after curative resection [1, 2]. Meanwhile, the Japanese
Gastric Cancer Treatment Guidelines 2010 (Version 3)
recommend observation without adjuvant treatment
after curative resection for patinets with pathologic
stage I (including pT1N1) gastric cancer [3]. Since
the two representative treatment guidelines present
inconsistent views on this issue, adding adjuvant
chemotherapy after surgical treatment in pT1N1
gastric cancer might depend on policies or preferences
of individual institutions, surgeons, and oncologists.
Although NCCN guidelines recommend adjuvant
chemotherapy which contains 5-FU ± leucovorin or
capecitabine, then fluoropyrimidiene-based chemora-
diation, then 5-FU ± leucovorin or capecitabine
(Category1) and chemotherapy for patients who have
undergone primary D2 lymph node dissection for any
T, N + (including pT1N1) gastric cancer [4], uncer-
tainty on the benefit of adjuvant chemotherapy and
excellent prognosis of pT1N1 gastric cancer make de-
cisions more difficult in clinical practice.
Although the prognosis of early gastric cancer
(EGC) is excellent with a 5-year survival rate after
curative resection of more than 90%, recurrence oc-
curs in approximately 1.4–7.0% of patients [5]. Several
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clinicopathological factors such as lymph node metastasis,
elevated gross type, lymphovascular invasion, perineural
invasion, a ratio of metastatic-to-retrieved lymph nodes of
greater than 0.07, advanced age, and differentiated histo-
logic type have been reported as predictive factors for
tumor recurrence in EGC [6–18]. Lymph node metastasis
is the most important prognostic factor of tumor recur-
rence after curative resection in EGC. A higher rate of re-
currence is expected for pT1N1 than for pT1N0 gastric
cancer. This might be the basis of NCCN guidelines.
However, studies have yet to evaluate tumor recurrence,
prognostic factors, or the survival benefit of adjuvant
chemotherapy for pT1N1 gastric cancer. Moreover, there
is no consensus on adjuvant chemotherapy for pT1N1
gastric cancer.
Therefore, the objective of this study was to evaluate
the oncological benefit of adjuvant chemotherapy after
curative surgery and identify factors predictive of tumor
recurrence for pT1N1 gastric cancer.
Methods
Patients
Clinicopathological data of 510 gastric cancer patients
who had undergone gastrectomy with lymph node dis-
section and finally diagnosed with pT1N1 between 1996
and 2010 at three institutions (Severance Hospital, Gang-
nam Severance Hospital, and Dongsan Medical Center)
were reviewed. Patients with prior gastric surgery, double
primary malignancies, and neoadjuvant chemotherapy
were excluded. This study was reviewed and approved by
the Institutional Review Boards of Severance Hospital,
Yonsei University College of Medicine (4–2014-0317) and
Dongsan Medical Center, Keimyung University School of
Medicine (2014–08-005).
Evaluation of clinicopathological variables
Clinicopathological features included for analysis in the
present study comprised age, sex, BMI, resection extent,
tumor location, gross type, histological type, number of
metastatic lymph nodes, adjuvant chemotherapy, and
tumor recurrence based on information listed in a pro-
spectively designed database. Conventional open gastrec-
tomy was performed in 422 patients. Minimally invasive
surgery including laparoscopic and robot-assisted gastrec-
tomy was performed in 88 patients. In all patients, sub-
total or total gastrectomy with D1+ or D2 lymph node
dissection was performed according to the guidelines of
the Japanese Gastric Cancer Association [3]. Histological
types were divided into differentiated type (including pap-
illary adenocarcinoma and well-to-moderately differenti-
ated tubular adenocarcinoma) and undifferentiated type
(including poorly differentiated tubular adenocarcinoma,
mucinous adenocarcinoma, and signet ring cell adeno-
carcinoma). Gross classification for EGC followed the
Japanese Endoscopy Society Classification. Gross types
were divided into elevated type (including EGC gross
types I and IIa) and non-elevated type (including EGC
gross types IIb, IIc, and III) [19]. For most patients, 5-FU-
based oral chemotherapeutic agents including Tegafur/ura-
cil (UFT), Furtulon, Titanium silicate (TS)-1, Tegacil,
Didox, and Mifurol were used. A few intravenous regimens
(5-fluorouracil + adriamycin, 5-fluorouracil + Cis-Dichloro-
Diamine-Platinum, mitomycin-C + 5-fluorouracil +Cytara-
bine, and 5-fluorouracil + adriamycin + mitomycin-C) were
used in some patients for adjuvant chemotherapy. Since
there is no established treatment strategy for pT1N1 gastric
cancer, decisions to administer chemotherapy in those
patients was based on their surgeons’ or oncologists’
preference. The prognostic effect of adjuvant chemo-
therapy was evaluated by comparing disease-free sur-
vival of patients with chemotherapy to those without
chemotherapy. Tumor recurrence was identified ac-
cording to standard clinical practices by evaluating pa-
tients every 3 or 6 months until 2 years after surgery
and then every 6 months thereafter for up to 5 years
after surgery with physical examinations, laboratory
tests, imaging (abdomen-pelvis CT and chest X-ray),
and endoscopy. Confirmation of recurrence by tissue
biopsy was done when possible. Liver magnetic reson-
ance imaging, bone scans, and positron emission tomo-
graphy scans were optional. The patterns of tumor
recurrence were classified as remnant stomach, peri-
toneal, hematogenous, distant lymph node, and mixed
type. Recurrence in remnant stomach included tumor
reappearance in the remnant stomach or anastomotic
site. Peritoneal seeding and Krukenberg tumor were con-
sidered as peritoneal recurrence. Hematogenous spread
was defined when there was involvement of specific intra-
abdominal or extra-abdominal organs such as liver, lung,
bone, brain, or adrenal glands. Recurrence in distant
lymph nodes included paraaortic, aortocaval, retroperi-
toneal, retropancreatic, and extra-abdominal lymph
node metastasis. Mixed type metastasis was considered
when cases had more than two types of metastasis.
Statistical analysis
Statistical analysis was carried out using SPSS® version
20.0 for Windows® (SPSS, Chicago, Illinois, USA). Cate-
gorical variables were compared using Chi-square or
Fisher’s exact tests. Univariate and multivariate analyses
for factors predictive of tumor recurrence after curative
resection for pT1N1 gastric cancer were carried out using
Cox proportional hazards model. Disease-free survival
curves were analyzed using the Kaplan-Meier method
with the duration of disease-free survival calculated in
months based on the length of time between primary
surgical treatment and the last follow-up or recurrence.
P values <0.05 were considered statistically significant.
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Results
Effect of adjuvant chemotherapy on disease-free survival
Among a total of 510 patients, 150 (29.4%) patients re-
ceived adjuvant chemotherapy after curative gastrectomy
and 360 (70.6%) patients underwent surgery only. Clinico-
pathological characteristics of the adjuvant chemotherapy
group and the surgery only group are summarized in
Table 1. The adjuvant chemotherapy group showed higher
incidence of two metastatic lymph nodes (43.3% vs.
31.9%) and lymphovascular invasion (60.7% vs. 41.7%)
compared to the surgery-only group. However, there was
no difference in disease-free survival between patients
with one metastatic lymph node and those with two
metastatic lymph nodes. There was no difference in
Table 1 Comparison of clinicopathological characteristics between adjuvant chemotherapy group and surgery-only group
Adjuvant chemotherapy (N = 150) Surgery-only (N = 360) P-value
N % N %
Age (years)
≤ 65 108 72.0 246 69.3 0.461
> 65 42 28.0 114 31.7
Gender 0.920
Male 95 63.3 225 62.5
Female 55 36.7 135 37.5
BMI (kg/m2) 0.990
< 25 102 68.0 245 68.1
≥ 25 48 32.0 115 31.9
Type of resection 0.060
STG 140 93.3 315 87.5
TG 10 6.7 45 12.5
Reconstruction 0.168
BI 70 46.7 174 48.3
BII 68 45.3 139 38.6
Roux-en-Y 12 8.0 47 13.1
Tumor location 0.416
Upper 9 6.0 20 5.6
Middle 44 29.3 128 35.6
Lower 97 64.7 212 58.9
Gross type 0.812
Elevated 30 20.0 77 21.4
Non-elevated 120 80.0 283 78.6
Depth of invasion 0.420
Mucosa 26 17.3 52 14.4
Submucosa 124 82.7 308 85.6
No. of metastatic LN 0.015
One 85 56.7 245 68.1
Two 65 43.3 115 31.9
Lymphovascular invasion <0.001
Positive 91 60.7 150 41.7
Negative 59 39.3 210 58.3
Histologic type 0.656
Differentiated 23 12.5 161 87.5
Undifferentiated 28 14.1 171 85.9
BMI body mass index, LN lymph node, N number, STG subtotal gastrectomy, TG total gastrectomy
P-value was italicized when less than 0.05
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disease-free survial between patients with lymphovas-
cular invasion and those without lymphovascular inva-
sion either. Five year disease-free survival rate was
91.8% in the adjuvant chemotherapy group and 94.6%
in the surgery only group without significant difference
(P = 0.815) (Fig. 1).
Prevalence and predictive factors of tumor recurrence
The median follow-up duration was 78 months (range,
5–216 months). The median time interval from surgical
treatment to tumor recurrence was 25.5 months (range,
5–177 months). Results of univariate and multivariate
analyses for identifying factors predictive of tumor re-
currence are shown in Table 2. Of 510 patients, 38
(7.5%) experienced recurrence while 472 (92.5%) had no
recurrence after surgical resection. In univariate analysis,
older age (>65 years), male gender, body mass index
(BMI) less than 25, elevated gross type, and differenti-
ated histologic type were associated with recurrence.
Type of resection, reconstruction method, tumor loca-
tion, depth of invasion, number of metastatic lymph
nodes, number of negative lymph nodes, lymphovascular
invasion, and adjuvant chemotherapy were not associ-
ated with tumor recurrence. The recurrence rate was
7.3% (11/150) in the adjuvant chemotherapy group, simi-
lar to that (7.5%, 27/360) in the surgery-only group.
Multivariate analysis showed that older age (>65 years
old) and male gender were significant predictive factors
for tumor recurrence. The 5-year disease free survival
rate was 85.9% in high risk patients satisfying both older
age and male gender and 96.3% in other patients
(P = 0.001). In high risk patients, there was no difference
in disease-free survival between the adjuvant chemother-
apy group and the surgery-only group either (P = 0.511).
Patterns of tumor recurrence
As shown in Table 3, 18 patients (47.4%) had tumor re-
currence within two years after surgery while 32 patients
(84.2%) had tumor recurrence within 5 years after sur-
gery. The most common sites of recurrence were distant
lymph nodes including paraaortic, aortocaval, retroperiton-
eal, retropancreatic, mediastinal, and supraclavicular lymph
nodes (11/38, 28.9%). Hematogenous spread (to liver, bone,
lungs, and adrenal glands) was present in 23.7% (9/38) of
patients. Seven patients (18.4%) showed recurrence in the
remnant stomach, two (5.3%) had peritoneal recurrence,
and nine (23.7%) showed mixed-type metastasis.
Discussion
The incidence of lymph node metastasis ranges from 10 to
15% in EGC with recurrence rate of 1.4–7.0% [5, 20–23].
In node-positive EGC, recurrence rates are higher (10.6–
14.8%) than those of node-negative EGC. Prognosis of
EGC after recurrence is very poor. Thus, some investiga-
tors have insisted that adjuvant chemotherapy should be
considered for node-positive EGC. However, the role of ad-
juvant chemotherapy for stage I node-positive EGC
(pT1N1) remains uncertain. In addition, there is no con-
sensus between the Japanese and NCCN guidelines [3, 4].
Therefore, surgeons sometimes experience confusion
on whether to administer adjuvant chemotherapy after
surgical treatment in pT1N1 gastric cancer.
Many reports have identified predictive factors for
tumor recurrence after surgical treatment in EGC.
Although several variables such as lymph node
Fig. 1 Comparison of disease-free survivals between adjuvant chemotherapy group and surgery-only group
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metastasis, lymphovascular invasion, perineural invasion,
submucosal invasion, a ratio of metastatic-to-retrieved
lymph nodes, elevated gross type, and advanced age have
been proposed as prognostic factors for EGC [6, 7, 9–18],
few reports are specific for pT1N1 gastric cancer. More-
over, there is no report on the effect of adjuvant chemo-
therapy on the prognosis of pT1N1 gastric cancer.
Accordingly, identifying high risk groups for tumor recur-
rence in patients with pT1N1 gastric cancer and clarifying
the role of adjuvant chemotherapy therein would provide
information useful for clinical practice.
In this study, tumor recurrence rate was 7.5% in
pT1N1 gastric cancer. Advanced age (>65 years) and
male gender were found to be independent predictive
Table 2 Univariate and multivariate analysis for the identification of predictive factors of recurrence
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age
≤ 65
> 65 2.625 1.384–4.981 0.003 2.541 1.336–4.831 0.004
Gender
Female
Male 2.401 1.101–5.240 0.028 2.217 1.013–4.854 0.046
BMI (kg/m2)
≥ 25
< 25 2.599 1.086–6.216 0.032 2.400 1.001–5.759 0.050
Type of resection
Subtotal
Total 0.718 0.221–2.334 0.581
Tumor location
Upper
Middle 0.871 0.193–3.932 0.857
Lower 1.167 0.276–4.928 0.834
Gross type
Non-elevated
Elevated 2.063 1.054–4.037 0.035 1.821 0.929–3.570 0.081
Depth of invasion
Mucosa
Submucosa 3.464 0.834–14.394 0.087
No. of metastatic LN
One
Two 1.194 0.623–2.288 0.594
No. of negative LN 0.996 0.975–1.017 0.697
Lymphatic invasion
Negative
Positive 1.800 0.939–3.454 0.077
Histologic type
Undifferentiated
Differentiated 2.251 1.163–4.356 0.016 1.548 0.776–3.087 0.215
Adjuvant CTx
No
Yes 0.919 0.455–1.859 0.815 0.952 0.467–1.937 0.891
BMI body mass index, CI confidence interval, CTx chemotherapy, HR hazard ratio, LN lymph nodes, LVI lymphovascular invasion
P-value was italicized when less than 0.05
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factors for tumor recurrence. In addition, adjuvant
chemotherapy did not decrease recurrence rate or pro-
long disease-free survival in pT1N1 gastric cancer in this
study. Considering the excellent prognosis of stage I gas-
tric cancer even pT1N1, the limited role of adjuvant
chemotherapy was expected to some degree. Therefore,
we analyzed risk factors for tumor recurrence and found
two independent risk factors (older age and male gender).
However, the reason why older age and male gender are in-
dependent risk factors for tumor recurrence is currently
unclear. This might be related to immunity or comorbidity.
However, we could not analyze details about immunity or
comorbity because few such data were available. Patients
satisfying these two factors showed significantly worse
prognosis than those without the two risk factors. Next,
the role of adjuvant chemotherapy in these high risk pa-
tients was analyzed. We found that, even in high risk pa-
tients, adjuvant chemotherapy offered no oncological
benefit. According to these results, adjuvant chemotherapy
might be unnecessary for pT1N1 gastric cancer patients.
In the present study, the number of metastatic lymph
nodes and the presence of lymphovascular invasion were
different between the adjuvant chemotherapy group and
the surgery only group. These results might reflect the
preference of patients and physicians to undergo and ad-
minister adjuvant chemotherapy for instances of two
metastatic lymph nodes compared to that for one meta-
static node. However, since metastatic lymph node num-
ber and lymphovascular invasion were not related to
tumor recurrence in patients with pT1N1 gastric cancer,
these factors should not be used to guide decisions on
whether to administer adjuvant chemotherapy.
The results of our study should be interpreted with
caution as any retrospective comparison has inherent
limitations. Due to excellent prognosis, only a small
number of patients experienced tumor recurrence. Al-
though data of patients were collected from three insti-
tutions for adequate analysis, small event number might
have resulted in some limitations in survival and risk
factor analyses. In addition, chemotherapeutic agents
were administered heterogeneously because of the devel-
opment of chemotherapeutic agents and unestablished
treatment guidelines. Although the NCCN guideline
(Version 2, 2013, Gastric cancer) recommends a few reg-
imens, it could not be used as the standard regimen be-
cause there is no evidence for their effectiveness in
pT1N1 gastric cancer. In addition, there was no definite
regimen recommended during the period of our study.
Such heterogenicity in regimens could result in confused
outcomes. Although large-scaled prospective randomized
trials are needed to clarify this issue, adjuvant chemother-
apy might be unnecessary because of excellent prognosis
of pT1N1 gastric cancer.
Conclusions
Adjuvant chemotherapy exhibited no significant benefit
for disease-free survival in patients with pT1N1 gastric
cancer, suggesting that adjuvant chemotherapy might be
unnecessary after curative surgery therein.
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